Login
$DSGN
$9.92 -$0.55 (5.25%) Live

$DSGN 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027

03 Aug 2026 8-K: Results of Operations and Financial Condition

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Design Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstand...

18 May 2026 8-K: Other Events

On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”).

28 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints

01 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

09 Mar 2026 8-K: Results of Operations and Financial Condition

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026

30 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

05 Nov 2025 8-K: Results of Operations and Financial Condition

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

10 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from non-human primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program

12 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2025, Design Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 15, 2025, the record date for the Annual Meeting, 56,768,678 shares of common stock were outstan...

07 May 2025 8-K: Results of Operations and Financial Condition

Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing

10 Mar 2025 8-K: Results of Operations and Financial Condition

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

13 Jan 2025 8-K: Regulation FD Disclosure

On January 13, 2025, Design Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated presentation is attached as Exhibit 99.1 to this Current Rep...

07 Nov 2024 8-K: Results of Operations and Financial Condition

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

05 Aug 2024 8-K: Results of Operations and Financial Condition

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

17 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 13, 2024, Design Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 18, 2024, the record date for the Annual Meeting, 56,495,039 shares of common stock were outstan...

08 May 2024 8-K: Results of Operations and Financial Condition

Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials

19 Mar 2024 8-K: Results of Operations and Financial Condition

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support